HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by KARTZINEL, R. Articles by CALNE, D. B. Search for Related Content PubMed PubMed Citation Articles by KARTZINEL, R. Articles by CALNE, D. B.

Studies with bromocriptine

III. Concomitant administration of caffeine to patients with idiopathic parkinsonism

From the Laboratory of Neuropharmacology, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health (Drs. Kartzinel and Calne), and the Department of Neurology, University of Rochester School of Medicine, Rochester, NY (Dr. Shoulson).

Caffeine was administered to six patients with idiopathic parkinsonism in an attempt to potentiate the therapeutic response of bromocriptine, a dopamine (DA) receptor agonist, by inhibition of phosphodiesterase. In a double-blind study at doses of 1,000 mg daily, caffeine failed to enhance the antiparkinsonian action of bromocriptine (40 mg daily) given concomitantly. Although effective in potentiating the action of levodopa and other agonists in animal models of parkinsonism, caffeine is inactive in parkinsonism in man.

Requests for reprints should be addressed to Bldg. 10, Room 6D20, NIH, 9000 Rockville Pike, Bethesda, MD 20014.

Received for publication November 17, 1975.

This article has been cited by other articles:

				D. Deleu, P. Jacob, P. Chand, S. Sarre, and A. Colwell Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology, September 12, 2006; 67(5): 897 - 899. [Abstract] [Full Text] [PDF]

				M. A. Schwarzschild, J.-F. Chen, and A. Ascherio Caffeinated clues and the promise of adenosine A2A antagonists in PD Neurology, April 23, 2002; 58(8): 1154 - 1160. [Abstract] [Full Text] [PDF]

				G. W. Ross, R. D. Abbott, H. Petrovitch, D. M. Morens, A. Grandinetti, K.-H. Tung, C. M. Tanner, K. H. Masaki, P. L. Blanchette, J. D. Curb, et al. Association of Coffee and Caffeine Intake With the Risk of Parkinson Disease JAMA, May 24, 2000; 283(20): 2674 - 2679. [Abstract] [Full Text] [PDF]